Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 11/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.44 |
| ▸ | PADI1 | Q9ULC6 | 1/20 | 0.44 |
| ▸ | PADI3 | Q9ULW8 | 1/20 | 0.44 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.44 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1983969 | 0.87 | FOLH1 (0.47) | FOLH1CA2C3AR1ALBPDE4A | |
| SCHEMBL12560085 | 0.87 | FOLH1 (0.47) | FOLH1CA2C3AR1ALBPDE4A | |
| SCHEMBL8975695 | 0.85 | FOLH1 (0.59) | FOLH1NAAA | |
| SCHEMBL10801725 | 0.85 | FOLH1 (0.59) | FOLH1NAAA | |
| SCHEMBL188590 | 0.84 | C3AR1 (0.52) | FOLH1CA2C3AR1ALBPDE4A | |
| SCHEMBL7925397 | 0.84 | C3AR1 (0.52) | FOLH1CA2C3AR1ALBPDE4A | |
| SCHEMBL188589 | 0.84 | C3AR1 (0.52) | FOLH1CA2C3AR1ALBPDE4A | |
| SCHEMBL14366289 | 0.84 | FOLH1 (0.45) | FOLH1CA2C3AR1ALBPDE4A | |
| SCHEMBL14366290 | 0.82 | C3AR1 (0.46) | FOLH1CA2C3AR1ALBPDE4A | |
| Alcohol SCHEMBL29029781 | 0.82 | CA2 (0.49) | FOLH1CA2C3AR1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276040-A1 | Peptidyl Arginine Deiminase Type IV Inhibitor | YOKOHAMA CITY UNIVERISITY (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070276040-A1 | Peptidyl Arginine Deiminase Type IV Inhibitor | YOKOHAMA CITY UNIVERISITY (JP) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276040-A1 | Peptidyl Arginine Deiminase Type IV Inhibitor | PADI4, PADI1, PADI2 | FOLH1 1237/4885CA2 545/4885C3AR1 581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.